Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204904 · ClinicalTrials.gov registry record
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
A clinical trial, sponsored by Genetix Biotherapeutics.
- Terminated
- Registry status
- 59
- Enrollment target
NCT02204904: Clinical Trial study, sponsored by Genetix Biotherapeutics.
NCT02204904 is a clinical trial that was terminated before completion, run by Genetix Biotherapeutics. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02204904 was terminated before completion, sponsored by Genetix Biotherapeutics.
- TERMINATED
- Registry status
- 59 participants
- Enrollment target
Study Summary
Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
Primary Outcome
TRM is defined as death due to any transplantation-related cause other than disease progression.
Interventions
- GENETIC Allo-HSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-12-06 |
Why NCT02204904 stopped before completion
NCT02204904 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Allo-HSCT is the first listed.
NCT02204904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02204904 about?
NCT02204904 is a clinical study titled "Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)". Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
What is the current status of trial NCT02204904?
This trial is currently terminated. The enrollment target is 59 participants. The study started on 2015-04. Estimated completion is 2019-12-06.
What interventions are being tested in trial NCT02204904?
The interventions under investigation include: Allo-HSCT (GENETIC).
Who is sponsoring clinical trial NCT02204904?
This trial is sponsored by Genetix Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia